MMI Completes First Symani® Clinical Cases in the U.S. Following FDA Commercial Authorization
May 01 2024 - 2:18PM
Business Wire
First in-human cases in the U.S. mark the start
of a new era in soft tissue open surgery
MMI (Medical Microinstruments, Inc.), a robotics company
dedicated to increasing treatment options and improving clinical
outcomes for patients with complex conditions, today announced the
completion of its first clinical cases in the United States using
the Symani® Surgical System. Both robotic-assisted microsurgical
procedures were performed at Penn Medicine, Penn Presbyterian
Medical Center, as a collaborative effort between the Department of
Orthopaedic Surgery and the Department of Surgery’s, Division of
Plastic Surgery.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240501137865/en/
The Symani® Surgical System: A
first-of-its kind robotic technology that uniquely addresses the
scale and complexities of microsurgery. (Photo: Business Wire)
The historic first U.S. procedures were reconstructive extremity
microsurgeries. In one case, the team performed a “free bone
transfer” procedure on a patient who suffered a traumatic injury;
the procedure involved transferring a segment of bone and skin from
their leg to a damaged bone in their forearm. The surgical team
revascularized the bone segment using the microsurgical robot to
reconnect the tiny blood vessels and facilitate successful
transfer. The second case involved a patient at risk for a leg
amputation due to an infected knee prosthesis with soft tissue
deficiency. The team repaired the severe knee wound with muscle and
skin from the patient’s back and robotically reconnected the blood
vessels to promote revascularization.
“The first U.S. cases are a paramount milestone in the global
expansion of the Symani Surgical System, and we’re honored to have
been able to work with Penn Medicine’s premiere orthopedic and
plastic surgery departments to achieve it,” said Mark Toland, CEO
at MMI. “Today marks the beginning of a new era in surgical
innovation, as patients across the country with conditions that
require complex microsurgical techniques, such as extremity
reconstruction, autologous breast reconstruction post cancer
resection and lymphedema repair, will now have expanded access to
treatment options.”
The U.S. Food and Drug Administration (FDA) recently granted De
Novo Classification to the Symani Surgical System, making it the
only commercially available platform in the U.S. for reconstructive
microsurgery. It uniquely addresses the scale and complexities of
microsurgery and supermicrosurgery such as the anastomosis and
suturing of small anatomical structures – like blood and lymphatic
vessels – during open surgical procedures. By allowing surgeons to
replicate the natural movements of the human hand at the micro
scale, it can expand treatment options for patients in need of
advanced surgical techniques. It is designed to help restore
quality of life for more patients, accelerate the number of
surgeons able to push the boundaries of complex procedures for
delicate anatomy, and enable hospitals to expand their open
surgical programs.
To learn more about MMI and the Symani Surgical System, visit
MMI’s website here: https://mmimicro.com.
About MMI
MMI (Medical Microinstruments, Inc.) is on a mission to advance
robotic technology that pushes the limits of soft tissue open
surgery and opens new opportunities for surgeons to restore quality
of life for more patients with complex conditions. The company was
founded in 2015 near Pisa, Italy, and its proprietary Symani®
Surgical System combines the world’s smallest wristed
microinstruments with tremor-reducing and motion-scaling
technologies to address significant unmet patient needs across the
globe. This first-of-its-kind surgical robotic platform for open,
soft tissue micro-level surgery can help address microvascular
repair and lymphatic repair. In Europe, it also addresses
peripheral nerve repair. The Symani System is authorized for use in
the U.S. by the FDA and is a CE Marked medical device in Europe.
MMI is backed by global investors including Fidelity Management
& Research Company, Andera Partners, BioStar, Deerfield
Management, Fountain Healthcare Partners, Panakès Partners, RA
Capital, Sambatech, and Wellington Partners.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240501137865/en/
Media Contact: Dan Ventresca Matter Health for MMI
MMI@matternow.com Investor Relations Contact: Lisa Croke
Lisa.Croke@mmimicro.com